Qiagen (QGEN) Q2 2024 earnings summary

Executive summary

• Q2 2024 net sales reached $496 million, up 1% at constant exchange rates (CER), with adjusted diluted EPS of $0.55, both exceeding outlook due to strong performance in core business and key product lines.

• Growth was led by QuantiFERON (+11% CER) and QIAstat-Dx (+12% CER), supported by new product launches and partnerships.

• Adjusted operating income margin rose to 28.4%, up 1 percentage point year-over-year, and free cash flow increased 56% to $129 million for the quarter.

• The full-year 2024 outlook was updated upward for both sales and adjusted EPS, reflecting robust H1 results and the NeuMoDx discontinuation decision.

Financial highlights

• Q2 2024 net sales were $496 million (+1% CER year-over-year); adjusted diluted EPS was $0.55 (+8% year-over-year); adjusted operating income was $141 million (+4% year-over-year).

• Adjusted operating income margin reached 28.4% of sales, up 1 percentage point year-over-year.

• Free cash flow increased 56% year-over-year in Q2 to $129 million and 86% in H1 to $225 million.

• Adjusted gross margin improved to 67.2% of sales, up 30 basis points year-over-year.

• Q2 2024 reported a net loss of $183.5 million due to restructuring and acquisition-related charges, but adjusted net income was $123 million.

Outlook and guidance

• Full-year 2024 net sales outlook updated to at least $1.985 billion CER, reflecting strong H1 and NeuMoDx phase-out.

• Adjusted EPS outlook raised to at least $2.16 CER for 2024; Q3 2024 net sales expected at least $495 million CER, up 4% year-over-year.

• Currency expected to have a negative 1 percentage point impact on full-year sales and $0.02 on adjusted EPS.

• Adjusted operating income margin target for FY 2024 is at least 28.5%.

• Adjusted tax rate expected at 19-20% for FY 2024.